Acceptability of an organ inventory for cancer screening across gender identity and intersex status
Moseson M, Ragosta S, Manchikanti Gómez A, Corman J, Zussman J, Lesser-Lee B, Reese S, Carter-Bolick I, Obedin-Maliver J. JNCI: Journal of the National Cancer Institute. December 2024. DOI: https://doi.org/10.1093/jnci/djae336
Objectives
To evaluate the acceptability and performance of an organ inventory as an alternative to asking about gender and/or sex assigned at birth in cancer screening.
Methods
We fielded an online, self-administered survey to a convenience sample of English- or Spanish-speaking transgender and gender-diverse (TGD), intersex, and cisgender people (>/=15 years) in the US. The survey contained an organ inventory developed with community input and questions regarding acceptability. The primary outcome was organ inventory acceptability by the four-item Acceptability of Intervention Measure (AIM). Additional outcomes included inter-method screening agreement between the organ inventory, gender, and sex assigned at birth.
Results
In 2022, 333 eligible individuals completed the survey; 44.4% cisgender, 34.2% TGD, and 14.1% intersex. Overall, participants rated the organ inventory as acceptable (median AIM score = 18/20, IQR: 16-20). Most (73%) found it easy to understand, and comfortable to complete (65%). Cancer screening eligibility varied based on the method used; relying solely on gender or sex data would have missed some eligible participants that the organ inventory identified.
Conclusions
Using an organ inventory as an alternative to gender or sex-based screening questions was acceptable, and has implications for addressing cancer screening disparities.